Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I, Tomasi A, Valdez SC, Wang W, Jiang H, Hartman J, Rodriguez HM, Kawas R, Sylvester S, Elias KA, Godinez G, Lee K, Anderson R, Sueoka S, Xu D, Wang Z, Djordjevic N, Malik FI, Morgans DJ Jr. Morgan BP, et al. Among authors: malik fi. ACS Med Chem Lett. 2010 Aug 20;1(9):472-7. doi: 10.1021/ml100138q. eCollection 2010 Dec 9. ACS Med Chem Lett. 2010. PMID: 24900233 Free PMC article.
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF Jr, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N; COSMIC-HF Investigators. Teerlink JR, et al. Among authors: malik fi. Lancet. 2016 Dec 10;388(10062):2895-2903. doi: 10.1016/S0140-6736(16)32049-9. Epub 2016 Dec 1. Lancet. 2016. PMID: 27914656 Free article. Clinical Trial.
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT. Povsic TJ, et al. Among authors: malik fi. Cardiovasc Drugs Ther. 2017 Aug;31(4):445-458. doi: 10.1007/s10557-017-6739-9. Cardiovasc Drugs Ther. 2017. PMID: 28735360 Review.
Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory.
O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. O'Connor CM, et al. Among authors: malik fi. J Am Coll Cardiol. 2018 Jan 30;71(4):443-453. doi: 10.1016/j.jacc.2017.11.048. J Am Coll Cardiol. 2018. PMID: 29389362 Free article. Review.
Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator.
Collibee SE, Bergnes G, Muci A, Browne WF 4th, Garard M, Hinken AC, Russell AJ, Suehiro I, Hartman J, Kawas R, Lu PP, Lee KH, Marquez D, Tomlinson M, Xu D, Kennedy A, Hwee D, Schaletzky J, Leung K, Malik FI, Morgans DJ Jr, Morgan BP. Collibee SE, et al. Among authors: malik fi. ACS Med Chem Lett. 2018 Feb 13;9(4):354-358. doi: 10.1021/acsmedchemlett.7b00546. eCollection 2018 Apr 12. ACS Med Chem Lett. 2018. PMID: 29670700 Free PMC article.
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Teerlink JR, et al. Among authors: malik fi. Eur J Heart Fail. 2020 Nov;22(11):2160-2171. doi: 10.1002/ejhf.2015. Epub 2020 Oct 27. Eur J Heart Fail. 2020. PMID: 32985088 Free PMC article. Clinical Trial.
Left ventricular systolic ejection time is an independent predictor of all-cause mortality in heart failure with reduced ejection fraction.
Alhakak AS, Sengeløv M, Jørgensen PG, Bruun NE, Johnsen C, Abildgaard U, Iversen AZ, Hansen TF, Teerlink JR, Malik FI, Solomon SD, Gislason G, Biering-Sørensen T. Alhakak AS, et al. Among authors: malik fi. Eur J Heart Fail. 2021 Feb;23(2):240-249. doi: 10.1002/ejhf.2022. Epub 2020 Oct 23. Eur J Heart Fail. 2021. PMID: 33034122 Free article.
Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study.
Felker GM, Solomon SD, McMurray JJV, Cleland JGF, Abbasi SA, Malik FI, Zhang H, Globe G, Teerlink JR; COSMIC-HF Investigators. Felker GM, et al. Among authors: malik fi. Circ Heart Fail. 2020 Dec;13(12):e007814. doi: 10.1161/CIRCHEARTFAILURE.120.007814. Epub 2020 Nov 12. Circ Heart Fail. 2020. PMID: 33176437 Free PMC article. Clinical Trial.
97 results